Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.
Company profile
Ticker
TENX
Exchange
Website
CEO
Anthony DiTonno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Life Newco, Inc. • PHPrecisionMed Inc. ...
IRS number
262593535
TENX stock data
News
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
1 Jul 22
12 Health Care Stocks Moving In Thursday's After-Market Session
30 Jun 22
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
30 Jun 22
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
29 Jun 22
LiveOne And 24 Stocks Moving Premarket
29 Jun 22
Press releases
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
25 May 22
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
23 May 22
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
18 May 22
Investment data
Securities sold
Number of investors
Calendar
15 May 22
2 Jul 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.87M | 2.87M | 2.87M | 2.87M | 2.87M | 2.87M |
| Cash burn (monthly) | 905.08K | 55.68K | (no burn) | (no burn) | 979.23K | 881.06K |
| Cash used (since last report) | 2.78M | 170.72K | n/a | n/a | 3M | 2.7M |
| Cash remaining | 93.47K | 2.7M | n/a | n/a | -133.89K | 167.11K |
| Runway (months of cash) | 0.1 | 48.5 | n/a | n/a | -0.1 | 0.2 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Jun 22 | June Sherie Almenoff | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 5,000 | 3.1K | 5,000 |
| 9 Jun 22 | Michael H. Davidson | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 5,000 | 3.1K | 5,000 |
| 9 Jun 22 | Doogan Declan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 5,000 | 3.1K | 5,000 |
| 9 Jun 22 | Chrisopher Thomas Giordano | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 200,000 | 124K | 200,000 |
| 9 Jun 22 | Robyn Hunter | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 6,250 | 3.88K | 6,250 |
Institutional ownership, Q1 2022
32.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 25 |
| Opened positions | 12 |
| Closed positions | 4 |
| Increased positions | 0 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 6.54M |
| Total shares | 8.08M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Gofen & Glossberg | 3.82M | $3.09M |
| Armistice Capital | 2.02M | $1.64M |
| Ikarian Capital | 735.1K | $596K |
| BLK Blackrock | 510.72K | $413K |
| Vanguard | 358.98K | $290K |
| PNC PNC Financial Services | 200K | $162K |
| STT State Street | 138.41K | $112K |
| Boothbay Fund Management | 71.81K | $58K |
| Renaissance Technologies | 67.43K | $55K |
| Financial Advisory Service | 58.33K | $47K |
Financial report summary
?Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
adequate, adherence, aim, ASU, cardiopulmonary, care, caring, chain, copy, counterpart, curtail, difficult, disruption, domiciliary, enable, expand, expedited, explanatory, exploited, foundation, furniture, government, headcount, health, highly, intent, IP, kidney, kind, Label, leverage, leveraging, listing, low, modest, negative, objective, opinion, outlined, outsourcing, Pat, PCT, preceding, Premium, prepaid, prescribed, presumption, principle, promise, promising, proof, refine, removing, request, robust, saving, science, Similarly, strategy, stroke, Subtopic, supplementally, traditional, unchanged, unredacted, variant
Removed:
abdominal, absorbed, accurate, acknowledged, activator, acute, acutely, addressed, adjunct, advanced, advice, afterload, Aid, ambulatory, American, amino, animal, announced, appetite, arbitration, arise, artery, assumption, assure, ATP, atrial, attributed, backward, Bank, baseline, beta, bicycle, binding, bioavailability, biological, blockade, Breakthrough, calcium, calculated, cancer, capillary, cardiac, cardiogenic, Cardiology, cardioprotective, cascade, causal, central, characterize, close, CML, combined, comorbidity, comparative, comparing, Comparison, compatibility, competitively, confirmed, confounded, congestion, consisting, contractility, conventional, criteria, CRO, cure, cytochrome, daily, damage, death, decline, decompensated, demand, demonstrate, demonstrated, denied, depending, Deregulation, desensitization, detailed, diarrhea, diastolic, differentiation, disbursed, discovered, discovery, distance, distention, diverse, dobutamine, dosing, dramatic, dysfunction, Economic, edema, efficacy, ejection, electrocardiographic, elevated, eligible, employed, employee, Encouraged, endothelin, endpoint, enrolled, entry, enzyme, ESC, estimate, European, evolving, examining, exceeding, expectation, explored, expression, extended, extensively, failed, failing, FC, filling, final, Finally, Finnish, fluid, formation, found, fraction, frequent, Functional, gastric, Gleevec, growth, halt, headache, hemodynamic, hemodynamically, HFpEF, HFrEF, history, home, Horizon, hospital, hospitalization, hospitalized, hypotension, impairment, improvement, improving, incidence, induce, induced, inhibit, inhibiting, inhibitor, initiated, inotropic, intolerance, Jebsen, journal, kinase, laboratory, lack, largely, lead, led, leg, Lender, leukemia, liver, loan, maintained, manuscript, marketed, mechanical, mechanism, mediated, metabolism, metabolite, metabolized, minimizing, mitochondrial, mmHg, monitoring, morbidity, mortality, mPAP, muscle, myeloid, myelosuppression, natriuretic, nausea, nitric, noncancer, nonclinical, notice, observed, Opening, opportunity, orphan, outpatient, output, outreach, overexpressed, oxide, PAP, partially, participated, passive, pathway, Paycheck, paying, PCWP, PDGF, PDGFRA, peptide, perfusion, pharmacologic, placebo, platelet, play, population, positive, potassium, PPP, prediction, preferable, preliminary, preload, preparing, preserve, preserved, pressure, prevalence, primary, produce, progression, projected, promissory, proposal, proposed, Protection, protein, protocol, proxy, published, pump, pyrimidine, qualified, randomized, RAP, rapid, rare, rash, receiving, reduced, regimen, regression, release, Relief, remodeling, replace, require, resistance, response, retention, reversal, reverse, revised, revolutionized, SBA, Scientific, secondary, security, sensitization, setting, shock, shorter, show, showing, signaling, Simdax, size, small, smooth, Society, specialty, specifically, sponsor, sponsored, stabilizing, statistically, stimuli, studied, sublicenseable, submission, submitted, subpart, successfully, summarize, supine, supporting, surgery, surrogate, sustained, symptomatic, systolic, test, text, therapy, thought, tired, tissue, tolerability, tolerated, trading, transition, transmission, Treasury, treat, treated, triple, troponin, type, typically, tyrosine, ultimately, unique, utilized, validated, vascular, vasculature, vasoconstriction, vasodilation, vasodilator, vasodilatory, ventricle, ventricular, vested, Virtual, vomiting, walk, wedge, week, weekly, wholly, withdraw, worldwide, worsening
Financial reports
Current reports
8-K
Entry into a Material Definitive Agreement
16 Jun 22
8-K
Departure of Directors or Certain Officers
10 Jun 22
8-K
Tenax Therapeutics Announces Successful
23 May 22
8-K
Tenax Therapeutics Announces Certain Securities and Nasdaq Disclosures
20 May 22
8-K
Other Events
24 Mar 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Feb 22
8-K
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
31 Jan 22
8-K
Entry into a Material Definitive Agreement
28 Jan 22
8-K
TENAX THERAPEUTICS January 2022 I Corporate Presentation www.tenaxthera.com NASDAQ TENX
24 Jan 22
8-K
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous
12 Jan 22
Registration and prospectus
424B3
Prospectus supplement
3 Jun 22
D
$8M in options / securities to be acquired, sold $8M, 1 investor
1 Jun 22
S-8
Registration of securities for employees
2 Sep 21
424B3
Prospectus supplement
2 Sep 21
D
$10M in options / securities to be acquired, sold $10M, 1 investor
20 Jul 21
424B3
Prospectus supplement
1 Oct 20
S-3/A
Shelf registration (amended)
11 Sep 20
S-3
Shelf registration
20 Aug 20
Other
EFFECT
Notice of effectiveness
6 Jun 22
CORRESP
Correspondence with SEC
31 May 22
UPLOAD
Letter from SEC
30 May 22
EFFECT
Notice of effectiveness
2 Sep 21
CORRESP
Correspondence with SEC
30 Aug 21
UPLOAD
Letter from SEC
29 Aug 21
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
10 Sep 20
UPLOAD
Letter from SEC
3 Sep 20
Ownership
SC 13G
TENAX THERAPEUTICS / ARMISTICE CAPITAL ownership change
21 Jun 22
SC 13D/A
TENAX THERAPEUTICS / ARMISTICE CAPITAL ownership change
17 Jun 22
4
TENAX THERAPEUTICS / Stuart Rich ownership change
10 Jun 22
4
TENAX THERAPEUTICS / GERALD T PROEHL ownership change
10 Jun 22
4
TENAX THERAPEUTICS / Robyn Hunter ownership change
10 Jun 22
4
TENAX THERAPEUTICS / Christopher Thomas Giordano ownership change
10 Jun 22
4
TENAX THERAPEUTICS / Declan Doogan ownership change
10 Jun 22
4
TENAX THERAPEUTICS / Michael H. Davidson ownership change
10 Jun 22
4
TENAX THERAPEUTICS / June Sherie Almenoff ownership change
10 Jun 22
SC 13D/A
TENAX THERAPEUTICS / ARMISTICE CAPITAL ownership change
20 May 22
Patents
Utility
Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan
31 Mar 22
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives.
Utility
Pharmaceutical compositions for subcutaneous administration of levosimendan
4 Jan 22
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives.
Utility
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
23 Dec 21
This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
Utility
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
17 Jun 21
This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
Utility
Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan
21 Oct 20
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives.
Reddit threads
Daily Discussion Thread - July 1st, 2022
1 Jul 22
Daily Plays June 28, 2022
28 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/27 $EVFM -old news Supreme Court decision on Roe v. Wade , $AFIB -FDA Clearance, Commercial Launch of AcQCross Line Extension , $EPZM -Ipsen to acquire U.S.-based Epizyme for $247 million., $TENX -labeling for the Company’s AXS-05 product
27 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/27 $EVFM -old news Supreme Court decision on Roe v. Wade , $AFIB -FDA Clearance, Commercial Launch of AcQCross Line Extension , $EPZM -Ipsen to acquire U.S.-based Epizyme for $247 million., $TENX -labeling for the Company’s AXS-05 product
27 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/27 $EVFM -old news Supreme Court decision on Roe v. Wade , $AFIB -FDA Clearance, Commercial Launch of AcQCross Line Extension , $EPZM -Ipsen to acquire U.S.-based Epizyme for $247 million., $TENX -labeling for the Company’s AXS-05 product
27 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/27 $EVFM -old news Supreme Court decision on Roe v. Wade , $AFIB -FDA Clearance, Commercial Launch of AcQCross Line Extension , $EPZM -Ipsen to acquire U.S.-based Epizyme for $247 million., $TENX -labeling for the Company’s AXS-05 product
27 Jun 22
Daily Discussion Thread - June 27th, 2022
27 Jun 22
Daily Discussion Thread - June 24th, 2022
24 Jun 22
Daily Discussion Thread - June 20th, 2022
20 Jun 22
Daily Discussion Thread - June 17th, 2022
17 Jun 22